TuHURA Biosciences (HURA) Stock Price, News & Analysis

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Key Stats

• Today's Range: $2.29 to $2.46
• 50-Day Range: $2.22 to $3.12
• 52-Week Range: $1.80 to $8.63
• Volume: 134,145 shs
• Average Volume: 233,080 shs
• Market Capitalization: $100.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.67
• Consensus Rating: Buy

TuHURA Biosciences Stock Analysis - MarketRank™

TuHURA Biosciences scored higher than 25% of companies evaluated by MarketBeat, and ranked 821st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

TuHURA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TuHURA Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TuHURA Biosciences has a P/B Ratio of 6.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HURA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TuHURA Biosciences does not currently pay a dividend.

Dividend Growth

TuHURA Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HURA.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

8 people have searched for HURA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

3 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.20% of the stock of TuHURA Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.62% of the stock of TuHURA Biosciences is held by institutions.

HURA Stock Analysis - Frequently Asked Questions

How have HURA shares performed this year?

TuHURA Biosciences' stock was trading at $4.09 at the beginning of the year. Since then, HURA stock has decreased by 43.8% and is now trading at $2.30.

How were TuHURA Biosciences' earnings last quarter?

TuHURA Biosciences, Inc. (NASDAQ:HURA) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02.

Who are TuHURA Biosciences' major shareholders?

TuHURA Biosciences' top institutional shareholders include Geode Capital Management LLC (1.33%) and Suncoast Equity Management (0.24%).

How do I buy shares of TuHURA Biosciences?

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 10/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HURA
• Previous Symbol: NASDAQ:HURA
• CIK: 1498382
• Web: N/A
• Phone: (813) 875-6600
• Fax: 604-608-5685
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TuHURA Biosciences: $12.67
• High Price Target: $15.00
• Low Price Target: $11.00
• Potential Upside/Downside: +443.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 291.69%
• Return on Assets: 122.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.00
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 6.85

Miscellaneous

• Outstanding Shares: 43,680,000
• Free Float: 43,593,000
• Market Cap: $101.73 million
• Optionable: N/A
• Beta: 0.04